Floatz Rating
B58/100
Confidence
Indicative
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
43Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02726659CT.gov Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Postpartum Depression
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Celecoxib (this asset) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | P3 | B · 58 |
| Allopregnan-3.Alpha.-Ol-20-One | Supernus Pharmaceuticals, Inc. | P3 | BBB |
| Sertraline | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | P4 | BB |
| Zuranolone | Biogen | P3 | BB |
| Gabapentin | Stanford University | P4 | BB |
| Escitalopram | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | P3 | BB |
| Lpcn 1154A | Lipocine Inc. | P3 | BB |
| Nora520 | DuKang Pharmaceuticals, Inc. | P2 | B |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Grace Lim, MD, MS | P2 | B |
+4 more in the Postpartum Depression cohort
Other indications for Celecoxib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis, Hip | — | P4 | BB · 71 |
| Osteoarthritis, Knee | — | P4 | BB · 69 |
| Bipolar Depression | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Allopregnan-3.Alpha.-Ol-20-OneSupernus Pharmaceuticals, Inc.BBB
- SertralineLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sBB
- ZuranoloneBiogenBB
- GabapentinStanford UniversityBB
- EscitalopramLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sBB
Citation
Floatz Terminal. Celecoxib in Postpartum Depression. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/celecoxib-postpartum-depression
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →